v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Grant Revenue $ 278,628
Operating Expenses:    
Research and development 333,334 402,704
General and administrative 914,569 973,865
Total Operating Expenses 1,247,903 1,376,569
Total Operating Loss (1,247,903) (1,097,941)
Other Expense:    
Interest expense (53,046) (63,661)
Net Loss (1,300,949) (1,161,602)
Net loss attributable to noncontrolling interest (10,495) (21,494)
Net loss attributable to common stockholders $ (1,290,454) $ (1,140,108)
Basic Loss Per Common Share $ (0.00) $ (0.00)
Diluted Loss Per Common Share $ (0.00) $ (0.00)
Weighted Average Number of Common Shares Outstanding - Basic 420,279,879 420,279,879
Weighted Average Number of Common Shares Outstanding - Diluted 420,279,879 420,279,879